InflaRx N.V.
IFRX$267M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaJENA74 employees
Drugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
IFRX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
IFX-1 + BSC
Severe COVID-19 Pneumonia
vilobelimab
Pyoderma Gangrenosum
Glucocorticoid (GC)
Granulomatosis With Polyangiitis (GPA)
CaCP29
Severe Sepsis
IFX-1
Hidradenitis Suppurativa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IFX-1 + BSC | Phase 3 | Severe COVID-19 Pneumonia | - | - |
vilobelimab | Phase 2 | Pyoderma Gangrenosum | - | - |
Glucocorticoid (GC) | Phase 2 | Granulomatosis With Polyangiitis (GPA) | - | - |
CaCP29 | Phase 2 | Severe Sepsis | - | - |
IFX-1 | Phase 2 | Hidradenitis Suppurativa | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply